## BEAM: Beam Therapeutics Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 7.9% in mid entry zone (4.0-10.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (0.5%) confirms momentum alignment. Outperforming sector by 6.5%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($23.47)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Nikko Asset Management Americas Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM**
- Source: MarketBeat | 20251214T110934 | Somewhat-Bullish | Relevance: 100%
- Nikko Asset Management Americas Inc. significantly increased its stake in Beam Therapeutics Inc. by 10.7% in Q2, raising its holdings to 4,726,799 shares valued at approximately $80.4 million. Despite recent misses on EPS and revenue estimates, analysts maintain a "Moderate Buy" rating for Beam Therapeutics with an average price target of $45.58. The company is actively developing precision genetic medicines, including treatments for sickle cell disease and alpha-1 antitrypsin deficiency.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Evercore ISI Gr | $35 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Evercore ISI Gr | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.02M) |
| Sells | 5 ($0.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 2 |

**Top Holders:**
- FMR, LLC: 11.5% (-9.8%)
- ARK Investment Manag: 10.9% (+24.8%)
- Farallon Capital Man: 9.9% (+0.5%)
- Vanguard Group Inc: 9.1% (-4.7%)
- Blackrock Inc.: 8.0% (+1.8%)

### Key Risks

1. High beta (2.22) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 7.1x requires aggressive growth execution.
3. High short interest (23.2%, 9.3 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 7.09 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (6.0x), low leverage (D/E 0.36). Institutional flow bullish (6 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.7B |
| Beta | 2.22 |
| 52W Range | $13.53 - $35.25 |
| Short Interest | 23.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 7.09 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 at 0.5% confirms short-term momentum alignment. AM_20 at 7.5% shows strong absolute momentum above own 20MA. Outperforming sector by 6.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.91% (CS: 90) | Strong |
| RSI_14 | 56.6 | Neutral |
| MACD Histogram | 0.26 | Bullish |
| vs SMA20 | 1.075x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.278x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $26.83
- **Stop Loss:** $23.47 (12.5% risk)
- **Target:** $31.87 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 357
- **Position Value:** $9,578.31
- **Portfolio %:** 9.58%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-24 (Est: $-1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.01 | $-1.10 | -8.9% |
| 2025Q2 | $-1.09 | $-1.00 | +8.4% |
| 2025Q1 | $-1.17 | $-1.24 | -5.9% |
| 2024Q4 | $-1.22 | $-1.09 | +10.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*